ML-SA5 is a MCOLN1 agonist that blocks autophagic flux by disrupting fusion between autophagosomes and lysosomes.

METHODS: 0.05 or 0.1 μM ML-SA5 was used to treat HeLa cells 1 hour and 4 hours after the application of agonists, and the LC3-II levels in HeLa cells were observed.
RESULTS ML-SA5 significantly increased the LC3-II levels. ML-SA5 regulates the LC3-II levels by stimulating the activity of MCOLN1 channels. [1]
METHODS: Vero cells stably expressing GFP-Lamp1 were transfected with pStrep-mCherry-CvpE. Twenty hours after transfection, cells were treated with DMSO or ML-SA5 (30 μM) for 4 hours. Then, cells were fixed and nucleic acids were stained with DAPI.
RESULTS ML-SA5 treatment completely blocked CvpE-induced cytoplasmic vacuolization. [2]

METHODS: Patu 8988 t cells were injected into the subcutaneous tissue of nude mice, and ML-SA5 (5 μM) was injected into solid tumors daily. Tumor volume was measured daily, and immunohistochemistry and immunoblot analysis were performed after death of mice.
RESULTS Administration of ML-SA5 profoundly promoted the survival of Patu 8988 t xenograft mice and inhibited tumor growth. [1]